ArticleAmerican journal of cancer research2025
The CXCR1 as a putative marker for cancer stem cell-like phenotypes in chemotherapy-resistant pancreatic ductal adenocarcinoma.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cancer stem cells (CSCs) are a rare but critical subpopulation in pancreatic ductal adenocarcinoma (PDAC), contributing to therapy resistance and disease relapse. The CXCR1 signaling axis has been implicated in CSC maintenance across multiple cancers. We investigated the role of CXCR1 in CSC-like phenotypes in PDAC by analyzing its expression, along with established CSC markers, in chemotherapy-resistant (GemR) and parental PDAC cell lines under various treatment conditions. GemR cells exhibited elevated levels of CXCR1, its ligand CXCL6, and CSC markers compared to parental lines. Gemcitabine treatment increased the expression of CXCR1 and CSC-associated markers in parental cells, suggesting therapy-induced enrichment of CSC-like populations. Additionally, GemR cells had a higher frequency of CD44
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.